Dr. Palmer on Molecular Abnormalities in Myeloproliferative Diseases
April 16th 2018Jeanne M. Palmer, MD, hematologist oncologist, Mayo Clinic, discusses molecular abnormalities in myeloproliferative diseases, including polycythemia vera (PV) and the use of next-generation sequencing in identifying these mutations.
Dr. Singh on Patient Selection for Immunotherapy in Bladder Cancer
March 2nd 2018Parminder Singh, MD, Hematologist/Oncologist, Mayo Clinic, discusses treatment selection for patients with bladder cancer. At this point, patient selection is based on the approval or labeling indications of the drug, where the patient lies in the spectrum of disease, and whether or not they have any alternative options.
Dr. Bryce on the Use of Abiraterone Versus Docetaxel in Patients With Prostate Cancer
February 28th 2018Alan H. Bryce, MD, assistant professor of medicine, Mayo Clinic, discusses the importance of individualized approaches in the use of abiraterone (Zytiga) versus docetaxel in patients with metastatic hormone-sensitive prostate cancer.